Rivaroxaban TecniGen 10 mg film-coated tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Rivaroxaban TecniGen contains the active substance rivaroxaban and is used in adults to:
Rivaroxaban belongs to a group of medications called antithrombotic agents. It works by blocking a clotting factor (factor Xa) and thus reducing the tendency of blood to form clots.
Do not take Rivaroxaban TecniGen:
Do not take this medication and inform your doctorif any of these circumstances apply to your case.
Warnings and precautions
Consult your doctor or pharmacist before starting to take rivaroxaban.
Be particularly careful with Rivaroxaban TecniGen
Inform your doctor if you have any of these situationsbefore taking rivaroxaban. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If you need surgery
Children and adolescents
Rivaroxaban 10 mg tablets are not recommended for children under 18 years of age.There is not enough information about their use in children and adolescents.
Other medications and Rivaroxaban TecniGen
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, including those obtained without a prescription.
If any of the above circumstances apply to you, inform your doctorbefore taking rivaroxaban, as the effect of rivaroxaban may be increased. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If your doctor considers that you have a higher risk of developing stomach or intestinal ulcers, they will recommend using a preventive treatment for ulcers in addition to rivaroxaban.
If any of the above circumstances apply to you, inform your doctorbefore taking rivaroxaban, as the effect of rivaroxaban may be decreased. Your doctor will decide if you should be treated with rivaroxaban and if you should be kept under closer observation.
Pregnancy and breastfeeding
Do not take rivaroxaban if you are pregnant or breastfeeding. If there is any possibility that you may become pregnant, use a reliable contraceptive while taking rivaroxaban. If you become pregnant while taking this medication, inform your doctor immediately, who will decide how you should be treated.
Driving and using machines
Rivaroxaban may cause dizziness (frequent side effect) or fainting (uncommon side effect) (see section 4, "Possible side effects"). You should not drive, ride a bicycle, or use tools or machines if you are affected by these symptoms.
Rivaroxaban TecniGen contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Rivaroxaban TecniGen contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Follow the administration instructions of this medication exactly as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
What dose to take
The recommended dose is one 10 mg rivaroxaban tablet once a day.
After at least 6 months of treatment for blood clots, the recommended dose is one 10 mg tablet once a day or one 20 mg tablet once a day. Your doctor has prescribed rivaroxaban 10 mg once a day.
Swallow the tablet, preferably with water. Rivaroxaban can be taken with or without food.
If you have difficulty swallowing the tablet whole, consult your doctor about other ways to take rivaroxaban. The tablet can be crushed and mixed with water or apple puree, immediately before taking it.
If necessary, your doctor may also administer the crushed rivaroxaban tablet through a gastric tube.
When to take Rivaroxaban TecniGen
Take the tablet every day, until your doctor indicates otherwise.
Try to take a tablet at the same time every day, to help you remember. The doctor will decide how long you should continue treatment.
To prevent the formation of blood clots in the veins after hip or knee replacement surgery:
Take the first tablet 6 to 10 hours after surgery.
If you have undergone major hip surgery, you will usually take tablets for 5 weeks.
If you have undergone major knee surgery, you will usually take tablets for 2 weeks.
If you take more Rivaroxaban TecniGen than you should
Contact your doctor immediately if you have taken too many tablets of this medication. Taking too much medication increases the risk of bleeding.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Rivaroxaban TecniGen
If you forget to take a dose, take it as soon as you remember. Take the next tablet the next day and, after that, take one tablet every day, as usual.
Do not take a double dose to make up for forgotten doses.
If you stop taking Rivaroxaban TecniGen
Do not stop treatment with rivaroxaban without first talking to your doctor, as rivaroxaban prevents the development of a serious condition.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, rivaroxaban can cause side effects, although not everyone will experience them.
Like other similar medications to reduce blood clotting, rivaroxaban can cause bleeding, which can be life-threatening. Excessive bleeding can cause a sudden drop in blood pressure (shock). In some cases, the bleeding may not be apparent.
Tell your doctor immediately if you experience any of the following side effects:
Your doctor will decide to keep you under closer observation or modify your treatment.
The frequency of these side effects is very rare (up to 1 in 10,000 people).
The frequencies of severe allergic reactions are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic edema; may affect up to 1 in 100 people).
General list of possible side effects
Frequent(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Frequency not known(cannot be estimated from available data)
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are side effects not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging and on each blister, after "CAD". The expiration date is the last day of the month indicated.
No special storage conditions are required.
Crushed tablets
Crushed tablets are stable in water or apple puree for up to 4 hours.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and any unused medicines at the SIGRE collection point in your pharmacy. Ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Composition of Rivaroxaban TecniGen
Tablet core: microcrystalline cellulose, sodium croscarmellose, lactose monohydrate, hypromellose, sodium lauryl sulfate, magnesium stearate, calcium silicate, corn starch.
Coating material: macrogol, hypromellose, lactose monohydrate, titanium dioxide (E-171), red iron oxide (E-172), yellow iron oxide (E-172).
Appearance of the product and package contents
Rivaroxaban TecniGen 10 mg film-coated tablets are pink, round, and biconvex, with a diameter of 6.0 mm.
Available in packages of 10 and 30 film-coated tablets.
Marketing authorization holder and manufacturer
Marketing authorization holder
Tecnimede España Industria Farmacéutica, S.A.
Avda. de Bruselas, 13, 3º D.
28108 Alcobendas (Madrid)
Spain
Manufacturer
Atlantic Pharma – Produções Farmacêuticas, S.A.
Rua da Tapada Grande, n.º 2
Abrunheira, 2710-089 Sintra
Portugal
Date of the last revision of this prospectus: January 2023
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/